Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis
- PMID: 7729900
- PMCID: PMC173241
- DOI: 10.1128/iai.63.5.1899-1905.1995
Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis
Abstract
Capsular glucuronoxylomannans (GXM) of Cryptococcus neoformans var. neoformans isolates from patients with recurrent cryptococcal meningitis were analyzed by 1H nuclear magnetic resonance spectroscopy and for reactivity with factor sera (Iatron, Tokyo, Japan). For each patient the initial and relapse isolates had previously been shown to be indistinguishable by DNA restriction fragment length polymorphism analysis. For patients J11 and J22 the GXM of the initial and relapse isolates were identical. For patients SB4 and SB6 the GXM of the initial and relapse isolates differed in structure and reactivity with factor sera. In patient SB4 the initial isolate had a serotype A/D structure, and the first relapse isolate had a serotype A structure. The second relapse isolate was a mixture of structures composed of serotype D components, glucuronomannan (GM), and a minor serotype A component. Analysis of the initial isolate from patient SB6 showed a structure composed mainly of serotype D, GM, and minor serotype A components and components not assigned to a particular serotype (N). The relapse isolate had the same composition as the initial isolate except for an increase in the serotype A component. This increase in the serotype A component of the relapse isolate resulted in a change in the serological specificity from serotype D to serotype A/D. The initial isolate from patient J9 had serotype D and GM structures. The first two relapse isolates had serotype D, N, and GM structures and a minor serotype A component. The third relapse isolate had mainly a serotype D structure. All the J9 isolates reacted only with serotype D-specific factor serum. These results indicate that some isolates obtained from patients with recurrent C. neoformans infections have undergone a change in GXM structure during the course of infection. The modification of GXM structure observed in some relapse isolates is reflected in changed serological properties. The results may have important implications for the design of vaccines and antibody-based therapeutic strategies against C. neoformans.
Similar articles
-
Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans serotype C as determined by 2D 1H NMR spectroscopy.Carbohydr Res. 1995 Oct 23;276(2):365-86. doi: 10.1016/0008-6215(95)00167-r. Carbohydr Res. 1995. PMID: 8542606
-
Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay.Infect Immun. 1995 May;63(5):1810-9. doi: 10.1128/iai.63.5.1810-1819.1995. Infect Immun. 1995. PMID: 7537249 Free PMC article.
-
Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans Cap70 as determined by 2D NMR spectroscopy.Carbohydr Res. 1996 Mar 22;283:95-110. doi: 10.1016/0008-6215(95)00397-5. Carbohydr Res. 1996. PMID: 8901265
-
Capsular polysaccharides of Cryptococcus neoformans.Rev Infect Dis. 1984 Sep-Oct;6(5):619-24. doi: 10.1093/clinids/6.5.619. Rev Infect Dis. 1984. PMID: 6209768 Review.
-
Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.Trends Microbiol. 2001 Sep;9(9):445-51. doi: 10.1016/s0966-842x(01)02134-5. Trends Microbiol. 2001. PMID: 11553457 Review.
Cited by
-
The capsule of the fungal pathogen Cryptococcus neoformans.Adv Appl Microbiol. 2009;68:133-216. doi: 10.1016/S0065-2164(09)01204-0. Adv Appl Microbiol. 2009. PMID: 19426855 Free PMC article. Review.
-
The Cryptococcus neoformans capsule: lessons from the use of optical tweezers and other biophysical tools.Front Microbiol. 2015 Jun 24;6:640. doi: 10.3389/fmicb.2015.00640. eCollection 2015. Front Microbiol. 2015. PMID: 26157436 Free PMC article. Review.
-
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Antimicrob Agents Chemother. 1998 Jun;42(6):1437-46. doi: 10.1128/AAC.42.6.1437. Antimicrob Agents Chemother. 1998. PMID: 9624491 Free PMC article.
-
Microreview: capsule-associated genes of Cryptococcus neoformans.Mycopathologia. 2007 Jan;163(1):1-8. doi: 10.1007/s11046-006-0083-0. Mycopathologia. 2007. PMID: 17216326 Review.
-
Aging as an emergent factor that contributes to phenotypic variation in Cryptococcus neoformans.Fungal Genet Biol. 2015 May;78:59-64. doi: 10.1016/j.fgb.2014.10.004. Epub 2014 Oct 13. Fungal Genet Biol. 2015. PMID: 25307541 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources